Abstract 280P
Background
Multiple studies in the past have elaborated the role of different risks stratification scores such as Sokal, Hasford, and Eutos (S.H.E.). These studies either correlated the risk stratification with survival, PFS, CcyR, MMR, or point BCR-ABL at different time intervals post-TKI. However, as we understand, all patients do not have a similar disease burden at the initiation of TKI. Also, using cut off level for different age group, gender, and disease burdens is an oversimplification of the disease remission criteria. There are very few studies on the rate (velocity) of the fall of BCR-ABL. The aim of this study was to compare the efficacy of various prognostic score in predicting the fall in BCR ABL over two years.
Methods
This is a prospective observational study comprising 653 (sample size predicted: 300) patients managed at a tertiary care center in north India based on a uniform treatment and evaluation protocol (Generic Imatinib 400 mg OD and three monthly RQ-PCR-BCR/ABL-IS). Statistics were done using Python-13.
Results
The median age of the study population was 43 years (16-87). On comparing the three risk groups of Sokal, the high-risk patients had the least fall in BCR-ABL at any time point up to 2 years post intiation of TKI. Whereas, there was no difference between low and intermediate risk. The difference in the three groups was not statistically significant. There was also no statistically significant difference in the rate of fall of BCR/ABL in the three risk groups of Hasford. The two risk groups of Eutos score had a significant difference in the rate of fall of BCR/ABL, the high risk having a lower rate in comparison to low risk.
Conclusions
Of the three scoring systems, the EUTOS score outperforms as a prognostic model using rate of fall of BCR-ABL in newly diagnosed CML-CP patients upto two years on Generic Imatinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract